ArticleFEBS open bio2023

Development of ADS051, an oral, gut-restricted, small molecule neutrophil modulator for the treatment of neutrophil-mediated inflammatory diseases.

Christopher K Murphy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.